Mississauga biotech firm gets $200 million-dollar shot in the arm


A Mississauga-based biotech firm has received $200 million in federal funds to build a new COVID-19 vaccine manufacturing facility within the city.
The funding was announced Tuesday morning — bringing a “made-in-Canada” solution for vaccine production in Peel Region. Resilience Biotechnologies Inc., a subsidiary of National Resilience Inc., specializes in vaccine manufacturing, development and assembly, and will use the funding to expand its facility
with a 45,000 square-foot upgrade, as well as add 205 new full-time jobs as it ramps up production in the fight against COVID- 19.
“(This) investment will not only boost Canadian manufacturing, it will also support good manufacturing jobs,” said Prime Minister Justin Trudeau, speaking alongside Innovation
Minister François- Philippe Champagne during an online press conference. “To rebuild from this pandemic, we’re investing in Canada.”
The facility will produce anywhere from 112 – 640 million doses of vaccine per year once the facility upgrades are complete, said Resilience CEO Rahul Singh.
“Resilience was founded during the pandemic to build a better system for manufacturing complex medicines to fight deadly diseases… will help prepare Canada for future pandemics
and strengthen the country’s biopharmaceutical ecosystem.

About the author

Asia Metro Editor

Surjit Singh Flora
editor@asiametro.ca

Leave a Comment